Advertisement
U.S. markets closed
  • S&P Futures

    5,179.75
    +12.25 (+0.24%)
     
  • Dow Futures

    38,318.00
    +80.00 (+0.21%)
     
  • Nasdaq Futures

    18,227.00
    +47.75 (+0.26%)
     
  • Russell 2000 Futures

    2,031.00
    +11.20 (+0.55%)
     
  • Crude Oil

    85.67
    +0.01 (+0.01%)
     
  • Gold

    2,377.00
    +2.90 (+0.12%)
     
  • Silver

    28.24
    -0.09 (-0.32%)
     
  • EUR/USD

    1.0650
    +0.0003 (+0.03%)
     
  • 10-Yr Bond

    4.4990
    -0.0770 (-1.68%)
     
  • Vix

    17.31
    +2.40 (+16.10%)
     
  • GBP/USD

    1.2456
    +0.0004 (+0.03%)
     
  • USD/JPY

    153.3650
    +0.1250 (+0.08%)
     
  • Bitcoin USD

    65,619.00
    +1,982.45 (+3.12%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,995.58
    +71.78 (+0.91%)
     
  • Nikkei 225

    38,905.26
    -618.29 (-1.56%)
     

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Alector, Inc.
Alector, Inc.

Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2023, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call.

The event will be webcast live under the investor relations section of Alector’s website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.

Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com

Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com


Advertisement